Why is clinical progress in acute myelogenous leukemia so slow?

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 1, 2008, Pages 1-3

  Rowe, Jacob M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CYTARABINE; DEXAMETHASONE; IMATINIB; MYELOABLATIVE AGENT; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG MEGADOSE; EDITORIAL; HUMAN; LEUKEMIA REMISSION; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; PUBLICATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, ACUTE; REMISSION INDUCTION;

EID: 40749083042     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2007.11.001     Document Type: Editorial

References (5)

1. Appelbaum F.R., Rowe J.M., Radich J., et al. Acute myeloid leukemia. Hematology. American Society of Hematology. Education Program (2001) 62-86
2. Jabbour E.J., Estey E., and Kantarjian H.M. Adult acute myeloid leukemia. Mayo Clinic Proceedings. Mayo Clinic 81 (2006) 247-260
3. Mayer R.J., Davis R.B., Schiffer C.A., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. The New England Journal of Medicine 331 (1994) 896-903
4. Moore J.O., George S.L., Dodge R.K., et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood 105 (2005) 3420-3427
5. Tubergen D.C., and Bleyer A. The leukemias. In: Behrman R.E., Kliegman R.M., and Jenson H.B. (Eds). Nelson textbook of pediatrics (2003), Saunders, Philadelphia 1694-1698